Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

2013; Elsevier BV; Volume: 121; Issue: 20 Linguagem: Inglês

10.1182/blood-2012-10-460063

ISSN

1528-0020

Autores

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, Carlo Visco, Yong Li, Roberto N. Miranda, Santiago Montes‐Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, Xiaoying Zhao, J. Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Z. Ai, Maurilio Ponzoni, Andrés J.M. Ferreri, Fan Zhou, Graham W. Slack, Randy D. Gascoyne, Meifeng Tu, Daina Variakojis, Weina Chen, Ronald S. Go, Miguel Á. Piris, Michael Møller, L. Jeffrey Medeiros, Ken H. Young,

Tópico(s)

CAR-T cell therapy research

Resumo

Key Points DLBCL patients with MYC/BCL2 coexpression demonstrate inferior prognosis and high-risk gene expression signatures.

Referência(s)